Msd Sub Merck Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MSD SUB MERCK, and what generic alternatives to MSD SUB MERCK drugs are available?
MSD SUB MERCK has fourteen approved drugs.
There are twenty US patents protecting MSD SUB MERCK drugs.
There are five hundred and forty-nine patent family members on MSD SUB MERCK drugs in sixty countries and one hundred and fifty-eight supplementary protection certificates in nineteen countries.
Summary for Msd Sub Merck
International Patents: | 549 |
US Patents: | 20 |
Tradenames: | 13 |
Ingredients: | 11 |
NDAs: | 14 |
Drugs and US Patents for Msd Sub Merck
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msd Sub Merck | JANUMET | metformin hydrochloride; sitagliptin phosphate | TABLET;ORAL | 022044-001 | Mar 30, 2007 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Msd Sub Merck | ISENTRESS | raltegravir potassium | TABLET;ORAL | 022145-001 | Oct 12, 2007 | RX | Yes | Yes | 8,771,733 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Msd Sub Merck | JANUMET | metformin hydrochloride; sitagliptin phosphate | TABLET;ORAL | 022044-001 | Mar 30, 2007 | RX | Yes | No | 7,326,708*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Msd Sub Merck
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Msd Sub Merck | JANUMET XR | metformin hydrochloride; sitagliptin phosphate | TABLET, EXTENDED RELEASE;ORAL | 202270-003 | Feb 2, 2012 | 7,459,428 | ⤷ Try a Trial |
Msd Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-002 | Dec 15, 2015 | 7,265,009 | ⤷ Try a Trial |
Msd Sub Merck | JANUMET XR | metformin hydrochloride; sitagliptin phosphate | TABLET, EXTENDED RELEASE;ORAL | 202270-002 | Feb 2, 2012 | 7,078,381 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MSD SUB MERCK drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 50 mg/500 mg and 50 mg/1000 mg | ➤ Subscribe | 2010-10-18 |
➤ Subscribe | Injection | 2 mg/mL, 100 mL vial | ➤ Subscribe | 2008-12-18 |
➤ Subscribe | Injection | 1 g/vial | ➤ Subscribe | 2013-06-20 |
➤ Subscribe | Ophthalmic Solution | 2% | ➤ Subscribe | 2005-10-11 |
➤ Subscribe | Extended-release Tablets | 100 mg/1000 mg | ➤ Subscribe | 2012-10-22 |
➤ Subscribe | Injection | 2 mg/mL, 10 mL vial | ➤ Subscribe | 2008-09-30 |
➤ Subscribe | Injection | 0.75 mg/mL, 100 mL vial | ➤ Subscribe | 2009-06-05 |
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2011-10-12 |
➤ Subscribe | Extended-release Capsules | 50 mg/500 mg and 50 mg/1000 mg | ➤ Subscribe | 2012-03-16 |
International Patents for Msd Sub Merck Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Austria | 462426 | ⤷ Try a Trial |
Canada | 2463976 | ⤷ Try a Trial |
Australia | 2005311671 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Msd Sub Merck Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2410844 | 2017006 | Norway | ⤷ Try a Trial | PRODUCT NAME: ELBASVIR ELLER ET FARMASOEYTISK; REG. NO/DATE: EU/1/16/1119 20160804 |
0509752 | C990041 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306 |
1506211 | CA 2014 00037 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.